Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 1/20 | 0.56 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.56 |
| ▸ | BRD4 | O60885 | 12/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | MERTK | Q12866 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19665726 | 1.00 | STK17B (0.56) | STK17BSTK17ABRD4ADORA2AADORA1 | |
| SCHEMBL19665693 | 0.86 | SIRT5 (0.41) | STK17BSTK17A | |
| SCHEMBL19665633 | 0.83 | STK17A (0.53) | STK17BSTK17ABRD4MEN1GAA | |
| SCHEMBL29290148 | 0.82 | LATS1 (0.44) | STK17BSTK17AMERTK | |
| SCHEMBL29802436 | 0.82 | STK17B (0.37) | STK17BSTK17ACA1CA2CA9 | |
| SCHEMBL12371624 | 0.80 | STK17B (0.54) | STK17BSTK17ABRD4ADORA2AADORA1 | |
| SCHEMBL28652855 | 0.80 | JAK3 (0.38) | STK17BSTK17A | |
| SCHEMBL29290149 | 0.78 | STK17A (0.44) | STK17BSTK17A | |
| SCHEMBL12968444 | 0.77 | STK17B (0.55) | STK17BSTK17ABRD4MEN1GAA | |
| SCHEMBL29290162 | 0.76 | JAK1 (0.35) | STK17BSTK17AMERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464287-B1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | CELGENE CORP (US) | 2022-06-08 | — | — | EP | disclosed |
| US-11344554-B2 | Animal and human anti-malarial agents | CELGENE CORPORATION (US) | 2022-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344554-B2 | Animal and human anti-malarial agents | HPRT1, UMPS, PNP | STK17B 3629/4885STK17A 3295/4885BRD4 4659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.